LexaGene Announces Collaboration with Ethos Veterinary Health


BEVERLY, Mass., April 04, 2018 (GLOBE NEWSWIRE) — LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, announced today that it has entered into collaboration with Ethos Veterinary Health, a veterinary health company with hospitals across the U.S. that provide advanced medical care for pets. This partnership will provide canine urine samples to LexaGene for testing on the Company’s LX6 prototype for more effective, rapid and on-site pathogen detection. The samples have been previously characterized using conventional technologies (MALDI-TOF / mass spectrometry) at its reference laboratory.

“In the coming weeks, veterinarians at Ethos will send LexaGene clinical annotated samples for processing, which will allow our team to continue to fine-tune and perfect our pathogen detection prototype’s testing capabilities,” said Dr. Jack Regan, LexaGene CEO. “This process is vital as we improve sensitivity to different isolates. We expect this to be a long-lasting collaboration as we work together to bring the best product possible to the veterinary market.”

“We’ve recently performed a market assessment for LexaGene’s technology by interviewing many emergency and critical care veterinarians, and – coupled with an internal financial assessment of the cost of conventional testing versus LexaGene’s projected testing costs – the results argue strongly for adopting LexaGene’s technology once available,” added Dr. Chand Khanna, Chief Science Officer, Ethos Veterinary Health. “We look forward to providing samples to LexaGene so that we can help them bring this product to market quickly and efficiently, ultimately enabling veterinarians to provide better care for clients in the near future.”

To be added to the LexaGene email distribution list, please subscribe on the Company website here.

To view the LexaGene website, click here.


About LexaGene Holdings Inc.
LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access, the LX6.  The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.  End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection.  The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about 1 hour.  The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

About Ethos Veterinary Health
Ethos is a veterinary health company with hospitals across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit ethosvet.com.

View Dr. Chand Khanna’s bio here.


The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207

LMU and Ethos Veterinary Health Collaborate on Research, Simulation, and Technology


WOBURN, Mass.–(BUSINESS WIRE)–Lincoln Memorial University (LMU) and Ethos Veterinary Health (Ethos) have entered into a unique collaborative relationship to advance their shared commitment to improve the profession through innovation in education. The relationship aims to transform learning in the veterinary community by leveraging Ethos’ unique commitment to learning and development and its online learning platform, VetBloom, and the strength of LMU’s pioneering educational model.

The multi-faceted partnership will allow for:

  • shared research on educational outcomes
  • advancing the use of simulations in clinical education
  • new ways of incorporating technology into training and continuous development

One component of the relationship consists of Ethos clinicians conducting virtual, case-based rounds with LMU students, providing them this type of learning very early in their education. “These rounds allow the LMU students to gain proficiency in clinical reasoning through case discussions,” said Linda Fineman, DVM, DACVIM (Oncology), Vice President of Learning and Development at Ethos. “At the same time, having the opportunity to give back to the next generation of veterinarians is rewarding for our clinicians.”

The partnership will capitalize on LMU’s educational expertise. LMU has a vast amount of experience and research building patient models through LMU’s Center for Innovation in Veterinary Education and Technology (CIVET). VetBloom currently has a unique anesthesia simulation and one area of mutual interest is in creating additional online simulations to expand their offerings. LMU and VetBloom share a goal of reaching underserved communities. Whether through VetBloom’s international reach, or LMU’s mission to serve the extensive Appalachian community, both organizations are focused on bringing advanced educational opportunities wherever they are needed.

“We’re very excited about this collaboration,” said John Weale, DVM, MS, Associate Dean, Clinical Relations and Outreach at LMU. “Not only does this benefit the teams at LMU and Ethos, but also the veterinary community at large.”

“This partnership is a living manifestation of our mutual commitment to advance veterinary learning by leveraging robust partnerships, rich technology, and succinct learning outcomes. It is, indeed, the future of education,” said Vice President and Dean of LMU-CVM, Dr. Jason Johnson.

The relationship promises to be fertile ground for ongoing exploration, and expansion of innovative programs.

About Lincoln Memorial University

Lincoln Memorial University is a non-profit, private, values-based learning community dedicated to providing educational experiences in the liberal arts and professional studies. The LMU-College of Veterinary Medicine is located on LMU’s main campus in Harrogate, Tennessee, with additional academic facilities in nearby Lee County, Virginia. LMU-CVM is an integral part of the University’s medical programs and provides real-world, community-based education in a collaborative learning environment. For more information visit vetmed.LMUnet.edu.

About Ethos Veterinary Health

Ethos is a veterinary health company with locations across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and collaboration. For more information visit ethosvet.com.

CNA Diagnostics and Ethos Veterinary Health Enter Strategic Partnership to Develop Suite of Diagnostic Tests for the Companion Animal Market


CNA Diagnostics Inc. (“CNAD”) and Ethos Veterinary Health (“Ethos”) are pleased to announce the parties have entered a strategic partnership to develop and distribute a suite of molecular diagnostic tests specifically designed to serve the companion animal market.

Read more…

VetDC Announces New TANOVEA®-CA1 Publication and State of the Art Presentation at the Veterinary Cancer Society 2017 Annual Conference


FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State of the Art presentation at the Veterinary Cancer Society (VCS) Annual Conference this past weekend in Portland, Oregon, with nearly 700 veterinary healthcare professionals in attendance.

Read more…

Ethos Veterinary Health Adds 15th Hospital: Vista Veterinary Specialists


Ethos Continues to Grow by Adding Select Practices

DENVER–(BUSINESS WIRE)–Vista Veterinary Specialists (Vista), a 24-hour specialty and emergency hospital located in Sacramento, Calif., joined Ethos Veterinary Health (Ethos) on August 2nd.

Vista is the 15th hospital owned and operated by Ethos. “Having Vista onboard adds to our growing set of veterinary hospitals and we are pleased to expand our presence in California,” said Ames Prentiss, CEO of Ethos.

For Ethos, partnering with hospitals that share its values, goals and commitment to innovation is paramount. Opportunities for growth and advancement of veterinary medicine, as well as individual growth, were of utmost importance for JT Vida, DVM, DACVS, owner of Vista. “When first contacted by Ethos, I was intrigued by the approach they are taking, which is very distinct from other veterinary groups,” said Dr. Vida. “Their concern for the individual coupled with a desire for the advancement of veterinary medicine really resonated with me. As discussions continued, it became apparent that Ethos could help Vista achieve so much more than we could by ourselves.”

Adding hospitals through mergers and acquisitions is part of Ethos’ long-term growth strategy. Having secured additional capital through a debt syndication, Ethos is looking to expand its hospital presence in current markets as well as new markets. “We are being selective and are in discussions with only those practices that best fit with Ethos – financially, geographically and culturally,” said Prentiss.

About Ethos Veterinary Health

Ethos Veterinary Health operates specialty and emergency veterinary hospitals with 15 locations cross the U.S. Ethos’ focus on team culture, professional growth of team members and scientific innovation leads to more fulfilled medical teams and improved care of patients and clients. For more information, visit ethosvet.com.

About Vista Veterinary Specialists

Vista Veterinary Specialists is a 24-hour emergency and referral practice in Sacramento, Calif., providing specialized and emergency care for companion animals. For more information, visit vistavets.com.

VetBloom Continues to Show Strong Growth


Expands Service to Asia and Forms Innovative Partnerships with ONCORE ePD and David Liss, RVT of Veterinary Training and Consulting

WOBURN, Mass.–(BUSINESS WIRE)–VetBloom, the cutting-edge, continuing education platform from Ethos Veterinary Health (Ethos), continues to rapidly expand its offerings and reach. VetBloom recently formed new partnerships with ONCORE ePD and David Liss, RVT, VTS (ECC, SAIM), CVPM, and is now launching in Asia in partnership with Veterinary Specialty Hospital (VSH) of Hong Kong, the first dedicated veterinary specialty hospital in the region.

Launching in June, VetBloom Asia contains popular and well-designed learning resources, tailored specifically to meet the needs of veterinary professionals at every stage of their career. Patrick Welch, DVM, MBA, DACVO, Chief Knowledge Officer of Ethos, explains why the Asian market is of particular interest. “We are seeing big changes in the way that veterinary professionals are able to access professional development resources. As many countries in Asia increase their adoption of formal continuing education requirements, the natural next step for VetBloom is to deliver innovative educational resources to the international veterinary community.”

VetBloom Asia will draw on the success of VetBloom’s U.S. operations together with the regional knowledge, relationships, and operating experience of the VSH Hong Kong team. “Veterinary continuing education is becoming more and more prevalent and easier to access as the demand from veterinary professionals grows,” said Dr. Alane Cahalane, CEO of VSH Hong Kong. “What’s really needed is a high caliber, comprehensive, up-to-date educational platform which can help to standardize the levels of professional knowledge in Asian countries. VetBloom Asia comprehensively fulfills those needs,” she continued.

On June 21st, 2017, in Quezon City, Philippines, Dr. Cahalane will deliver a complimentary learning event sponsored by VetBloom Asia for veterinary professionals in the area. For information and reservations please contact info@vsh.com.hk.

VetBloom also recently entered into partnerships with U.K.-based education provider, ONCORE ePD and David Liss, RVT. Since 2011, ONCORE ePD has been a pioneer of tutor-led, interactive online veterinary education covering a diverse range of subjects. ONCORE founder, Jill Macdonald, Dip AVN (Surg), RVN, FHEA, first became aware of VetBloom shortly after its launch in 2015 and has kept abreast of developments since that time. “I’m really impressed with the VetBloom learning platform and the commitment to quality and consistency of education offered,” said Macdonald. The product team, led by Jeffrey Johnson, M.Ed., has done excellent work and we are delighted to have the opportunity to collaborate.”

Dr. Welch sees great value in working with Jill and ONCORE within the context of a partnership. “Student feedback from ONCORE courses is fantastic and learners really appreciate the tutor mentorship and communication throughout. This type of online learning is not as prevalent in the U.S., and we’re excited to be working with Jill and ONCORE to launch these first modules,” he said.

Two instructor led modules – Patient-Friendly Practice: Dogs and Patient-Friendly Practice: Cats are currently in development for North American distribution and are scheduled for release in Q4 2017. For more information and to pre-register, please email contact@vetbloom.com.

David Liss, RVT, VTS (ECC, SAIM), CVPM is a renowned technician educator, lecturing internationally, authoring numerous articles and book chapters, and serving on various technician association committees. The partnership with David creates a unique synergy between his expertise and content, and the technology, online community and international reach of the VetBloom platform. This collaboration will allow VetBloom to offer more premium webinars and on-demand training for veterinary technicians and assistants.

About VetBloom

VetBloom is an innovative learning ecosystem featuring the expertise of the finest veterinary professionals in the industry, along with cutting-edge online instruction. Team members learn through direct and virtual instruction, interactive case-based scenarios and 3D simulations. VetBloom allows veterinary professionals to advance their skills from anywhere in the world. For more information visit vetbloom.com.

About Ethos Veterinary Health

Ethos is a veterinary health company with fourteen locations across the U.S. providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information visit ethosvet.com.

ACI and Ethos Veterinary Health Form New Clinical Trial Network


New Opportunity for Rapid Approval of Innovative Therapies for the Animal Health Market

WOBURN, Mass. (March 8, 2017) — Animal Clinical Investigation (ACI) and Ethos Veterinary Health (Ethos) have formed a strategic alliance offering a new mechanism to deliver market approval of pharmaceuticals and therapeutics in Animal Health. This relationship offers a unique opportunity for collaboration with organizations in the pharmaceutical industry, diagnostic developers and medical device companies.

The two companies are establishing a multi-specialty clinical trial network comprised of a geographically diverse, nationwide collection of Ethos veterinary hospitals. They are selected based on their interest and experience in clinical research, and their depth and strength in the veterinary specialties of internal medicine, dermatology, oncology, emergency and critical care medicine, diagnostic imaging and surgery.

“This is an exciting partnership for Ethos. It will ensure that we are on the forefront of medical discoveries through the participation of our motivated doctors trained in the rigor of conducting clinical trials by ACI, a leading group in veterinary medicine that oversees trial delivery.”

Keith Richter, DVM, MSEL, DACVIM
Chief Medical Officer

ACI, focused on complex medical problems in animals and the design and execution of clinical trials, has been a leader in bringing clinical trials into the private practice setting. Adding the Ethos multi-specialty trial network to ACI’s previously assembled group expands its reach beyond oncology and dermatology.

“Speaking on the new ACI-Ethos clinical trial network, Kristen Khanna, PhD, MBA, stated that, “We look forward to continuing to expand ACI’s role in clinical trial conduct in specialty medicine by joining with Ethos investigators and their staff.  Ethos already practices medicine at the highest level – this opportunity allows Ethos and ACI to share our science-driven mindset with study sponsors and pet owners.”

Kristen Khanna, PhD, MBA
ACI Chief Executive Officer

The opportunity for rapid and successful approval of innovative therapies is a key benefit to study sponsors, based on the following:

  • Rapid accrual of data, resulting in faster studies, is enabled by the substantial caseload offered by the Ethos network and the optimized trial participation through ACI’s management
  • Highly motivated and experienced clinicians and medical monitoring ensure quality data
  • Ethos’ strategic focus on scientific innovation

Clinical studies in the areas of orthopedics, pain management, gastrointestinal disorders, immune mediated disease, oncology and the management of sepsis in dogs are currently being planned and will be among the first to be launched by the new ACI-Ethos multi-specialty network.

Ethos Diagnostic Science Conducts Accuracy Testing for Samsung

, ,

Ethos Diagnostic Science was recently contracted by Samsung to study the accuracy of the new PT10V blood analyzer as Samsung prepared to enter the US Animal Health market. The small, point-of-care chemistry analyzer had been evaluated by Samsung in Korea prior to then, but it had not been studied against any reference standards.

Using industry recommendations for the validation of new laboratory assays methods, Ethos Diagnostic Science compared all instruments by testing several hundred canine, feline and equine blood specimens covering a wide range of values. Standard statistical methods for evaluating correlation – comparing the accuracy of the new analyzer with results obtained, on the same samples, from the reference analyzers – were utilized. The results showed excellent and acceptable data for all of the dog and cat samples, and nearly all of the horse specimens.

Dr. Andrew Loar, Vice President of Laboratories for Ethos Veterinary Health, said, “Of the hundreds of samples evaluated during the study, no operative or functional errors occurred, showing consistent and reliable results.” The findings were also useful for establishing the analyzer’s reference intervals (normal ranges) for all three species.

This was part of a collaborative effort between Samsung and Henry Schein.  … Read this article

New Hospital Network Known as Ethos Veterinary Health


With 13 hospitals from coast to coast, Ethos has not ruled out expansion.
Ethos is made up of 13 referral hospitals stretching from the northeastern United States to Southern California. Each location will retain the name of its respective group: IVG Hospitals, Premier Veterinary Group, Wheat Ridge Animal Hospital and Veterinary Specialty Hospital… Read this article